ALZAI developed a 100% non-invasive, highly sensitive, and low-cost tool capable of population-level risk screening for Alzheimer's Disease. ALZAI delivers AI-driven AD risk assessment enabling pre-symptomatic intervention to identify patients at-risk, stratify risk by years, and quantify risk by confidence level. The Proof-of-Concept is complete on over 500,000 real world patients period. ALZAI is designed to address a major unmet need and help rewrite the future of Alzheimer’s Disease.

Alzheimer's Disease (AD) is a growing multi-hundred-billion dollar market for treatment ($350B+ in the US alone) as AD is epidemic in senior populations. Every major Pharma company has a product pipeline for AD therapies and prophylaxis ($3.7B+). Early detection and prevention are crucial, which could save healthcare systems trillions of dollars in the future. Today, there are expensive diagnostic tools, there are no population risk-screening tools for AD.  ALZAI is exactly that, a highly sensitive screening tool for Alzheimer's Disease. ALZAI is addressing this major unmet need for Healthcare Providers seeking quality of care, Insurers and Governments seeking efficiency and prevention and Pharma seeking to save time and expense on clinical trials.

ALZAI Health

Org chart

Teams

Offices